Rotarex mechanical debulking: The Leipzig experience in patients

Similar documents
How do I use mechanical debulking for the treatment of arterial occlusions

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

Rotarex mechanical thrombectomythe first line option for thrombotic occlusions?

Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience

Mechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips.

Update on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany

COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert

Latest Insights from the LEVANT II study and sub-group analysis

Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions

Long-term results with interwoven nitinol stents vs. BMS vs. DCB

The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience

Update from Korea on the Lutonix SFA registry 12 month data

Dierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany

The Illumina FIH study with a next generation DES 12-months results

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

Alternative concepts for drug delivery in BTK arteries the LIMBO project

Novel concept for drug delivery in infrapopliteal arteries The LIMBO trial

14F OD Ovation Abdominal Stent Graft System

Lutonix DCB in BTK Update on the BTK real world registry and RCT

Michael K. W. Lichtenberg, MD, FESC Westfälische Wilhelms-Universität Münster. Dierk Scheinert, M.D. Universitätsklinikum Leipzig AöR

Update on the Ranger clinical trial programme

OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD

Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial

SAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Do we really need a stent in long SFA lesions? No: DEB is the answer

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

Straub Endovascular System &

New approaches for drug delivery in BTK arteries

LUTONIX DCB in BTK Update on the BTK clinical program & single center experience

Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD

Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy

LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:

BTK Case Studies Joseph Cardenas, MD AZ Heart & Vascular, Yuma, AZ

LIFESTREAM TM First look at the BOLSTER 2-year follow up data

BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

EffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

The essentials for BTK procedures: wires, balloons, what else

Plaque Excision Infrainguinal PAD An update on this nonstenting alternative, with intermediate-term results of the ongoing TALON Registry.

ILLUMENATE FIH Direct DCB Cohort 12-Month Results

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

When and how to use distal protection devices for lower extremity revascularization. Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

Maximizing Outcomes in a complex population with Drug-coated balloon

SFA CTO Lesion Management laser or directional atherectomy?

Rescue procedures in acute visceral ischemia

Tom Eisele, Benedikt M. Muenz, and Grigorios Korosoglou. Department of Cardiology & Vascular Medicine, GRN Hospital Weinheim, Weinheim, Germany

Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -

Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research

Massimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany

Koen Keirse, MD RZ Tienen, Belgium

Critical limb ischemia due to an occlusion of an aorto-biiliac prothesis step by step case presentation and decision making

The Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD

Potential Conflicts of Interest

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

Safety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses

Excimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA

CLI Treatment Using Long and Scoring Balloons

Treating in-stent occlusions with the Rotarex catheter : The ROBINSON study

Use of Laser In BTK Disease (CLI)

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease

DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

DISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.

TOBA Trial 12 months Results

Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry

DCB in my practice: How the evidence influences my strategy. Yang-Jin Park

Disclosures. Tips and Tricks for Tibial Intervention. Tibial intervention overview

January 23, Vascular and oncological interventional radiology Paris Descartes University

Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

Appropriate Device Selection for Endovascular Procedures

Are DES and DEB worth the cost in BTK interventions?

MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together

RANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators

Specificities for infrapopliteal stents

OCT guided procedures in peripheral intervention

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA

Device Evolution. Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance. Where Do We Stand? 4/18/2015

The Utility of Atherectomy and the Jetstream Atherectomy System

Why and where do I use mechanical debulking for the treatment of arterial occlusions?

Turbo-Power. Laser atherectomy catheter. The standard. for ISR

Study of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery

Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?

The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint

Is a Stent or Scaffold Necessary in The SFA?

The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan

Crossing the Long SFA CTO

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

Diagnosis and Management of Femoral Access Site Complications IV: Novel Techniques for Endovascular Rescue

Shockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany

Transcription:

Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany

Disclosure Speaker name: Dierk Scheinert I have the following potential conflicts of interest to report: Consulting: Abbott, Angioslide, Atheromed, Biotronik, Boston Scientific, Cook Medical, Cordis, Covidien, CR Bard, Gardia Medical, Hemoteq,Intact Vascular Inc., Medtronic, Ostial Inc, TriReme Medical, Trivascular, Upstream Peripheral Technologies

Thrombus-Containing Lesions Scenario 1: Acute Occlusions Chronic calf claudicant, boths sides Sudden hip and thigh pain with descompensation on the right side (4 days)

Thrombus-Containing Lesions Scenario 2: Embolic Occlusion Acute onset of pain Pale foot, sensory loss, motoric function intact

Thrombus-Containing Lesions Scenario 3: Subacute Occlusions Previous iliac-femoral endovascular revasc. Sub-acute in-stent occlusion (2 months)

Thrombus-Containing Lesions Scenario 4: Bypass reocclusion Right femoro-popliteal bypass Right iliaco-femoral bypass Femoro-popliteal bypass occlusion since 7 months

Thrombus-Containing Lesions Specific strategies are needed to open the vessel and to avoid distal embolization: - Thrombus aspiration - Thrombolysis - Mechanical thrombectomy (Rotarex)

Local bleeding after 12h low-dose thrombolysis

Rotarex-Catheter (Straub-Medical) ROTAREX ROTAREX S Multilayer braided 40 000 rpm Removal Suction Fragmentation - Transport

Thrombus-Containing Lesions Scenario 1: Acute Occlusions

Thrombus-Containing Lesions Scenario 2: Embolic Occlusion

Thrombus-Containing Lesions Scenario 3: Subacute Occlusions Rotarex 8F + Fluency spot-stenting

Thrombus-Containing Lesions Scenario 4: Bypass reocclusion Right femoro-popliteal bypass Right iliaco-femoral bypass Femoro-popliteal bypass occlusion since 7 months

Scenario 4 Rotarex 6 F 3-vessel BTK run-off No distal protection Immediate proximal and distal anastomotic post-balooning

Scenario 4

Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients - Single center registry: - Use of Thrombectomy device in OPAD patients - Safety and efficacy - Consecutive patient enrollment - Real world scenario - 1.809 patients treated (from 1/2005 11/2013) - 1.572 patients were analyzable (86,9%)

Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Intervention Feature - Native virgin arteries - Surgical bypasses - Redo procedures - In-stent procedures 1203 Procedures

Rotarex mechanical debulking in native arteries: Demographic characteristics (n=1203) Age, Mean ± SD (n) 66.7 ± 12.1 (1203) Male gender, n(%) 805 (66.9) Medical History, n(%) Obesity 396 (32.9) Smoking 573 (47.6) Dyslipidemia 795 (66.1) Diabetes 482 (40.1) Insulin-dependent DM 85 (17.6*) Hypertension 957 (79.6) Coronary Artery Disease 360 (29.9) Cerebrovascular disease 122 (10.1) Renal Impairment 146 (12.1) Dialysis 18 (1.5) Previous anticoagulation 87 (7.2) Table 1. Clinical characteristics of 1203 patients treated with Mechanical Debulking for plain native arteries. * among diabetic patients

Rotarex mechanical debulking in native arteries: Onset of symptoms Acute (<14 days) 211 (17.5) Subacute (< 3 months) 314 (26.1) Chronic (> 3 months) 678 (56.4)

Rotarex mechanical debulking in native arteries: Clinical status Rutherford class on admission Rutherford Score Patient with events, n(%) 0 0 1 17 (1.4) 2 188 (15.6) 3 363 (30.2) 4 452 (37.6) 5 134 (11.1) 6 49 (4.1) Total 1203 (100) Table 2. Baseline Rutherford scores among patients at enrollment Debulking Devices on native vessels

Rotarex mechanical debulking in native arteries: Angiographic and procedural characteristics Total Vascular access sites 1203 Antegrade 739 (61.5%) Crossover 413 (34.3%) Retrograde 51 (4.2%) Sheath diameter device (French) 6 844 (70.2) 8 359 (29.8) Mean lesion lenght (cm) 11.7 (2-24.8) Intervention area AIC 13 (1.1%) SFA 835 (69.4%) Popliteal 114 (9.5%) SFA + Popliteal 169 (14.0%) Proximal BTK 49 (4.1%) Other 23 (1.9%) Table 3. Overall Angiographic and procedural characteristics among 1203 patients treated with Mechanical debulking devices for plain native arteries.

Rotarex mechanical debulking in native arteries: Angiographic and procedural characteristics Type of lesion (complain symptoms) n(%) Calcification 1169 * No/mild 396 (33.9) Moderate 464 (39.7) Severe 309 (26.4) Intervention Feature 1203 De-novo lesions 789 (65.6) Previous Balloon Angioplasty 414 (34.4) * Loss of 34 patients, due to inadequate images

Rotarex mechanical debulking in native arteries: Acute results Procedural success rate: 1139 (94.7% ) Main performed procedure Rotational Thrombectomy alone: 255 (21.2%) Rotational Thrombectomy + PTA: 597 (49.6%) Additional Stenting: 251 (29.2%) Additional Thrombolysis: 113 (9.4%) Mean time follow-up: 12 ± 2.4 months

Rotarex mechanical debulking in native arteries: Acute results - Complications Table 6. Major Adverse Events (MAE) to 12-months post-intervention MAE All events n (%) Perforation 22 (1.8) Bleeding 29 (2.4) Dissection 108 (9) Acute closure 27 (2.2) Emboli 87 (7.2) Infection 14 (1.2)

Rotarex mechanical debulking in native arteries: Acute results Stenting-rate: 29.2 % Full lesion stenting: 7.6 % Focal stenting: 21.6 %

Rotarex mechanical debulking in native arteries: Clinical Follow-up: 30-day results Major Adverse Events (MAE) to 30 postoperative day MAE Events (%) Death 19 1.6 MI * 13 1.1 TLR ** 25 2.1 TVR *** 7 0.6 Major Amputation 17 1.4 Total 81 6.7 Table 4. Major Adverse Events (MAE) to 30 postoperative day. Values are rate numbers (%) of observations Myocardial infarction ** Target-lesion revascularization *** Target-vessel revascularization

Rotarex mechanical debulking in native arteries: Clinical Follow-up: 12 months results Major Adverse Events (MAE) to 12 month MAE Events (%) Death 101 8.4 MI * 28 2.3 TLR ** 127 10.6 TVR *** 41 3.4 Major Amputation 47 3.9

Rotarex mechanical debulking in native arteries: Clinical Follow-up: 12 months results 500 73.2% of claudicants with improvement of Rutherford class 400 300 Number of patients 200 Baseline Follow up 100 0 RF 0 RF 1 RF 2 RF 3 RF 4 RF 5 RF 6 Rutherford classes (RF)

Rotarex mechanical debulking in native arteries: Summary The use of the Rotarex-catheter in native peripheral arteries with acute, subacute and chronic lesions resulted in a high procedural success rate of 94.7% The low rate of procedural complications and 30 day clinical events supports the safety of the device in a broad range of lesions The 12-months TLR rate of 10.6% together with a marked improvement of the clinical status demonstrates the clinal effectivness at 1 year.

Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany